Evidence map›Paper›PMID 38706565›Full record

ArticleFrontiers in nutrition2024

Untargeted metabolomics based on ultra-high performance liquid chromatography-mass spectrometry/MS reveals the lipid-lowering mechanism of taurine in hyperlipidemia mice.

Xinzhe Guo, Tong Ou, Xinyu Yang, Qi Song, Lin Zhu, Shengquan Mi, Jing Zhang, Yanzhen Zhang, Wen Chen, Junxia Guo

Abstract read
In one paragraph

Article in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. AnmSystems · 2026
    Article
  4. Article
  5. Article
  6. Metabolomics: Uncovering Insights into Obesity and Diabetes.International journal of molecular sciences · 2025
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xinzhe GuoBeijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing, China.
Tong OuBeijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing, China.
Xinyu YangBeijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing, China.
Qi SongBeijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing, China.
Lin ZhuBeijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing, China.
Shengquan MiBeijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing, China.
Jing ZhangBeijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing, China.
Yanzhen ZhangBeijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing, China.
Wen ChenBeijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing, China.
Junxia GuoBeijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Taurine has a prominent lipid-lowering effect on hyperlipidemia. However, a comprehensive analysis of the effects of taurine on endogenous metabolites in hyperlipidemia has not been documented. This study aimed to explore the impact of taurine on multiple metabolites associated with hyperlipidemia. Methods: The hyperlipidemic mouse model was induced by high-fat diet (HFD). Taurine was administered via oral gavage at doses of 700  mg/kg/day for 14  weeks. Evaluation of body weight, serum lipid levels, and histopathology of the liver and adipose tissue was performed to confirm the lipid-lowering effect of taurine. Ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS)-based metabonomics analyses of serum, urine, feces, and liver, coupled with multivariate data analysis, were conducted to assess changes in the endogenous metabolites. Results and discussion: Biochemical and histological examinations demonstrated that taurine administration prevented weight gain and dyslipidemia, and alleviated lipid deposition in the liver and adipose tissue in hyperlipidemic mice. A total of 76 differential metabolites were identified by UPLC-MS-based metabolomics approach, mainly involving BAs, GPs, SMs, DGs, TGs, PUFAs and amino acids. Taurine was found to partially prevent HFDinduced abnormalities in the aforementioned metabolites. Using KEGG database and MetaboAnalyst software, it was determined that taurine effectively alleviates metabolic abnormalities caused by HFD, including fatty acid metabolism, sphingolipid metabolism, glycerophospholipid metabolism, diacylglycerol metabolism, amino acid metabolism, bile acid and taurine metabolism, taurine and hypotaurine metabolism. Moreover, DGs, GPs and SMs, and taurine itself may serve as active metabolites in facilitating various anti-hyperlipidemia signal pathways associated with taurine. This study provides new evidence for taurine to prevent hyperlipidemia.

Indexed as

hyperlipidemialipid-lowering effectmetabolomicstaurineultra-high performance liquid chromatography-mass spectrometry (UPLC-MS)

Identifiers

PMID38706565
PMCPMC11066166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.